CTOs on the Move

Incyte

www.incyte.com

 
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines that will meet serious unmet medical needs in oncology and other diseases. Incyte is a company driven by innovation, and we believe that investment in cutting-edge science and the rigorous pursuit of R&D excellence can translate into new medicines for serious unmet medical needs that positively impact patients` lives. Incyte has a diverse and growing portfolio of first-in-class and best-in-class product candidates, including both small and large molecules. Incyte is headquartered in Wilmington, Delaware with operations in 10 European countries and Japan. Our more than ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.incyte.com
  • 1801 Augustine Cut-off
    Wilmington, DE USA 19880
  • Phone: 855.446.2983

Executives

Name Title Contact Details
Martin Dillender
 Director of IT Profile
Nari Narayanan
 Director - IT Security Profile
Nari Narayanan
 Associate Vice President, Chief Information Security Officer Profile
Roger Hoilman
 Chief Information Officer Profile
Steven Lerner
 Chief Information Officer Profile

Similar Companies

Front Range Biosciences

Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.

Impact Biomedicines

Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.

HiberCell

Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.

Semler Research Center Pvt.

Semler Research Center Pvt. Ltd. is a North Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zealand Pharma

Changing lives with next generation peptide therapeutics